All In MedTech

FDA Clearance Tracker · P220025

LimFlow System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Sep 11, 2023 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Sep 11, 2023

Approved

Time to decision

315 days

Received Oct 31, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P220025
Device name
LimFlow System
Applicant
LimFlow, Inc.
Applicant location
San Jose, CA
Received
Oct 31, 2022
Decided
Sep 11, 2023
Decision
Approved
Supplements
8 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code QWN

FDA's approval statement

As written in FDA's record.

Approval for The LimFlow System. The device is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code QWN (Stent graft, infrapopliteal, venous arterialization).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for LimFlow, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

3 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.